abstract |
A PD-L1 axis-binding antagonist for use in treating a patient suffering from bladder cancer, in which a tumor sample obtained from the patient has been determined to have a detectable PD-L1 expression level in tumor infiltrating immune cells comprising about 1% or more, about 5% or more, or about 10% or more of the tumor sample, and wherein the tumor sample obtained from the patient has been determined to be a tumor luminal subtype. |